Fractyl Health Inc (GUTS) Stock Price, Quote & News

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term r...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 902 8800

Website: fractyl.com

Address:

3 Van de Graaff Drive, Suite 200, Burlington, United States

PB09 Feb. 3 at 11:15 PM

$GUTS lot of upcoming catalyst, hopefully won’t get fucked. Invested heavy as the management team looks solid, product is solid, 51-60% institution ownership, $2 low price target, need one good news to get this over $1.

1 · Reply

CP9999 Feb. 3 at 10:53 PM

$GUTS absolute junk. Watching it go all the way down to zero. Bye bye money

0 · Reply

bigchouse Feb. 3 at 9:07 PM

$GUTS The borrow rates aren't that high yet. We need to see three digit rates for any short squeeze to take place or really good news. Start, Min, Max, Latest (Borrow Rates)

1 · Reply

dumberdore Feb. 3 at 8:08 PM

$GUTS I think it would make a lot of sense for the CEO to discuss the results. There’s two sets of results (1) where the difference in treatment and control is 4.5% vs 7.5% (post Tirzepatide) with p-value of 0.07 (2) where the difference in treatment and control is 4.2% vs 13.3% (post GLP-1 treatment only for patients who had above median GLP-1 weight loss) with p value of 0.004 So why was the difference not as pronounced with tirzepatide? Is it because tirzepatide is just extremely effective anyways? This is what dropped the stock price. The CEO and the company should definitely focus on this part. To me, tirzepatide works well because that physiology. Tirzepatide uses GLP-1 and GIP to suppress hunger. So even 6 months after treatment those patients just didn’t have the appetite to eat so they never gained as much weight back. That’s physiology not a failure of Revita. What could have Revita done more if patients post tirzepatide already weren’t gaining much weight.

1 · Reply

bigchouse Feb. 3 at 8:02 PM

$GUTS Soon.

1 · Reply

audiobookprisonstories Feb. 3 at 7:42 PM

$GUTS lower volume only good sign lets see

0 · Reply

GreenEnergy2022 Feb. 3 at 7:24 PM

$GUTS 📌 Sanity check: 1) High Q burn , low on cash = Dilution risk. 2) Under 1$ = Split/delist risk 3) all dead cat bounce will be sold = People wants to get out

0 · Reply

BioRich Feb. 3 at 7:22 PM

$GUTS Full chart to come, but in order to 2x your money from here, $GUTS has to just go back to $0.90/share. We can cry over spilled milk, or jump all over this opportunity. I, for one, have no tears left to shed so I'm jumping like Jordan. Cheers!

1 · Reply

tmpl Feb. 3 at 6:57 PM

$GUTS speechless on the falloff. It is abnormal manipulation, makes me wonder who and why...

0 · Reply

Excessive_ Feb. 3 at 6:56 PM

$GUTS The next binary event will destroy what is left here. You guys still waiting for a bounce? Smart money already left😬

1 · Reply

Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts

Jan 30, 2026, 11:46 AM EST - 4 days ago

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS

Jan 29, 2026, 1:48 PM EST - 5 days ago

Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product

Jan 29, 2026, 12:32 PM EST - 5 days ago

Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript

Jan 29, 2026, 7:00 AM EST - 5 days ago

Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

Jan 6, 2026, 7:00 AM EST - 4 weeks ago

Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness

Jan 5, 2026, 7:00 AM EST - 4 weeks ago

Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category

Dec 15, 2025, 5:45 PM EST - 7 weeks ago

Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones

Dec 2, 2025, 7:00 AM EST - 2 months ago

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Dec 1, 2025, 7:00 AM EST - 2 months ago

Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 8:21 PM EST - 2 months ago

Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 2 months ago

Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027

Nov 5, 2025, 7:00 AM EST - 3 months ago

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

Oct 7, 2025, 7:00 AM EDT - 4 months ago

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

Oct 1, 2025, 5:14 AM EDT - 4 months ago

Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang

Sep 26, 2025, 11:07 AM EDT - 4 months ago

Fractyl Health, Inc. - Special Call

Sep 26, 2025, 7:41 AM EDT - 4 months ago

Fractyl Health says experimental procedure helps maintain weight-loss in study

Sep 26, 2025, 7:05 AM EDT - 4 months ago

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Sep 26, 2025, 7:00 AM EDT - 4 months ago

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

Sep 5, 2025, 6:05 PM EDT - 5 months ago

Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward

Sep 3, 2025, 7:00 AM EDT - 5 months ago

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

Aug 12, 2025, 8:00 PM EDT - 6 months ago

Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 6 months ago

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Aug 7, 2025, 4:05 PM EDT - 6 months ago

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Aug 6, 2025, 8:30 AM EDT - 6 months ago

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

Aug 5, 2025, 4:15 PM EDT - 6 months ago

Fractyl Health Announces Proposed Public Offering

Aug 5, 2025, 4:02 PM EDT - 6 months ago

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Jul 16, 2025, 10:13 AM EDT - 7 months ago

Fractyl Health: Speculative Buy With Binary Risk

Jun 23, 2025, 7:40 AM EDT - 8 months ago

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Jun 23, 2025, 7:30 AM EDT - 8 months ago

Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Jun 18, 2025, 7:00 AM EDT - 8 months ago

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Jun 13, 2025, 7:00 AM EDT - 8 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 7:00 AM EDT - 8 months ago

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

May 19, 2025, 7:00 AM EDT - 9 months ago

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

May 17, 2025, 7:15 AM EDT - 9 months ago

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 14, 2025, 9:25 AM EDT - 9 months ago

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

May 13, 2025, 8:43 PM EDT - 9 months ago

Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 9 months ago

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

May 6, 2025, 7:00 AM EDT - 9 months ago

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Apr 28, 2025, 4:30 PM EDT - 10 months ago

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Apr 1, 2025, 7:00 AM EDT - 11 months ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 3, 2025, 8:01 PM EST - 1 year ago

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 1 year ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 7:00 AM EST - 1 year ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 1 year ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 1 year ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 1 year ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Nov 26, 2024, 7:00 AM EST - 1 year ago

Fractyl Health to Participate in the Upcoming December Conferences

Nov 14, 2024, 11:01 PM EST - 1 year ago

Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

PB09 Feb. 3 at 11:15 PM

1 · Reply

CP9999 Feb. 3 at 10:53 PM

$GUTS absolute junk. Watching it go all the way down to zero. Bye bye money

0 · Reply

bigchouse Feb. 3 at 9:07 PM

$GUTS The borrow rates aren't that high yet. We need to see three digit rates for any short squeeze to take place or really good news. Start, Min, Max, Latest (Borrow Rates)

1 · Reply

dumberdore Feb. 3 at 8:08 PM

1 · Reply

bigchouse Feb. 3 at 8:02 PM

$GUTS Soon.

1 · Reply

audiobookprisonstories Feb. 3 at 7:42 PM

$GUTS lower volume only good sign lets see

0 · Reply

GreenEnergy2022 Feb. 3 at 7:24 PM

$GUTS 📌 Sanity check: 1) High Q burn , low on cash = Dilution risk. 2) Under 1$ = Split/delist risk 3) all dead cat bounce will be sold = People wants to get out

0 · Reply

BioRich Feb. 3 at 7:22 PM

1 · Reply

tmpl Feb. 3 at 6:57 PM

$GUTS speechless on the falloff. It is abnormal manipulation, makes me wonder who and why...

0 · Reply

Excessive_ Feb. 3 at 6:56 PM

$GUTS The next binary event will destroy what is left here. You guys still waiting for a bounce? Smart money already left😬

1 · Reply

Blandula Feb. 3 at 6:35 PM

$GUTS short volume ratio 2/2/26: 67!!! It's getting worse day by day

0 · Reply

Justrise07 Feb. 3 at 6:15 PM

$GUTS Alright ! Welcome $NVO $LLY $PYPL members who join is to recover your loss or 3x profit! Let’s go

0 · Reply

Catmando3 Feb. 3 at 6:06 PM

$GUTS is this the bottom?

0 · Reply

robinhood1982 Feb. 3 at 5:42 PM

$GUTS give me moaaarrrr. MC now below cash on hand. 80% down in a week as if the company doesn't have anything. Ill buy more blood in the street.

0 · Reply

Excessive_ Feb. 3 at 5:41 PM

$GUTS The scary part is most would have bounced right away. THIS POS FINDS A NEW LOW EVERYDAY!

1 · Reply

Justrise07 Feb. 3 at 5:21 PM

$NVO to recover all moving to $GUTS for 3x ride with news $LLY

0 · Reply

BioRich Feb. 3 at 4:59 PM

$APLS Was looking to streamline my portfolio and free up cash to buy more $GUTS, but this post by Zacks immediately changed my mind. Thanks Zacks! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply